M R Semenchuk

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain
    M R Semenchuk
    Department of Neurology, University of Arizona, Tucson 85743, USA
    Neurology 57:1583-8. 2001
  2. ncbi request reprint Avinza Elan
    Marilyn R Semenchuk
    Curr Opin Investig Drugs 3:1369-72. 2002
  3. ncbi request reprint Efficacy of sustained-release bupropion in neuropathic pain: an open-label study
    M R Semenchuk
    Neurology Clinic, University of Arizona, Tucson 85711, USA
    Clin J Pain 16:6-11. 2000

Detail Information

Publications3

  1. ncbi request reprint Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain
    M R Semenchuk
    Department of Neurology, University of Arizona, Tucson 85743, USA
    Neurology 57:1583-8. 2001
    ..To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain...
  2. ncbi request reprint Avinza Elan
    Marilyn R Semenchuk
    Curr Opin Investig Drugs 3:1369-72. 2002
    ..It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806]...
  3. ncbi request reprint Efficacy of sustained-release bupropion in neuropathic pain: an open-label study
    M R Semenchuk
    Neurology Clinic, University of Arizona, Tucson 85711, USA
    Clin J Pain 16:6-11. 2000
    ..The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain...